BMS: biologics 75% of portfolio, will continue to invest in capabilities
Bristol-Myers Squibb has reported its third quarter revenues and an evolving operational model that includes a greater investment in R&D.
Archives for October 27, 2016
Bespak welcomes availability of Cimzia autoinjector on the UK NHS
Bespak says the availability of the autoinjector version of UCB’s Cimzia on the UK National Health Service (NHS) is a validation of its delivery technology.
Nordic Nanovector ASA signs second ADC deal in a month
Nordic Nanovector ASA and Heidelberg Pharma GmbH will develop antibody drug conjugate (ADC) treatments for leukaemias under a deal agreed this week.
Lonza ups 2016 forecast citing Q3 biopharma gains; says capex will be higher
Lonza has raised its 2016 guidance and predicted higher spending on manufacturing equipment after growth of its biopharma businesses in the third quarter.